Y-90 ibritumomab tiuxetan
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Y-90 ibritumomab tiuxetan, covering 2018-01-23 to 2021-05-25. Get the full timeline:
Most recent: Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]